Evidence and references reviewed: 10 November 2026.
Immunosuppressants reduce selected immune responses to prevent transplant rejection or control immune-mediated disease. The group includes small molecules and biologics with different targets and risks. A transplant regimen, a topical treatment and a cytokine-targeted antibody should not be treated as interchangeable approaches.1,2,3
What is immunosuppression, and which cells are targeted?
Immunosuppressive medicines reduce selected parts of the body’s innate and adaptive immune responses. Some suppress T-cell activation, others impede lymphocyte proliferation, and biologic medicines can selectively block TNF, interleukins or cell-surface proteins. Each pathway has a distinct therapeutic and safety profile. Organ transplantation, rheumatoid arthritis, inflammatory bowel disease, psoriasis and lupus require different combinations and targets; a regimen appropriate for one disease must not be copied to another.
| Target or pathway | Drug examples | Main clinical effect |
|---|---|---|
| Calcineurin/NFAT | Tacrolimus, cyclosporine | Reduce T-cell cytokine transcription, including IL-2-related activation. |
| mTOR | Sirolimus, everolimus | Reduce growth-factor-mediated lymphocyte proliferation. |
| Purine metabolism | Mycophenolate, azathioprine | Restrict lymphocyte proliferation through distinct nucleotide metabolic mechanisms. |
| Glucocorticoid receptor | Prednisone, methylprednisolone | Broad anti-inflammatory and immune regulatory transcriptional effects. |
| TNF/selected cytokines | Adalimumab and other biologics | Block disease-specific inflammatory mediators. |
| B-cell CD20 | Rituximab | Deplete selected B-cell populations and impair some vaccine responses. |
Immunosuppression is not absolute elimination of immunity. The degree of infection risk depends on dose, duration, combined drugs, underlying illness, age and specific pathway. Conversely, no one class has a universal “safe” profile for every patient or infection.1,2,3
Principal mechanisms
| Example | Target and action | Clinical implication |
|---|---|---|
| Tacrolimus | Binds FKBP-12; the complex inhibits calcineurin and downstream cytokine signalling. | It does not work by simply chelating intracellular calcium.1 |
| Sirolimus | Binds FKBP-12 but inhibits mTOR, not calcineurin. | Suppresses cytokine-driven lymphocyte proliferation through a different pathway.4 |
| Mycophenolate mofetil | Prodrug of mycophenolic acid, an IMPDH inhibitor that reduces de novo guanosine synthesis. | Mechanism and metabolism differ from calcineurin inhibitors.2 |
| Azathioprine | A thiopurine immunosuppressant with metabolism-dependent toxicity. | TPMT and NUDT15 status can affect myelotoxicity risk.5 |
| Rituximab | CD20-directed antibody targeting B cells. | Requires assessment for hepatitis B reactivation and infusion-related risks.6 |
| Adalimumab | TNF blockade. | Latent tuberculosis and other infection risks require assessment.3 |
Why tacrolimus and sirolimus are not equivalent
Tacrolimus binds FKBP-12; this complex inhibits calcineurin and downstream NFAT-dependent cytokine transcription. Cyclosporine achieves calcineurin inhibition through a different intracellular binding protein (cyclophilin). Sirolimus also binds FKBP-12 but inhibits mTOR rather than calcineurin, thereby limiting cytokine-driven cell-cycle progression.1,4
Nephrotoxicity, hypertension, diabetes, electrolyte effects and neurotoxicity can occur with calcineurin inhibitors. Sirolimus has additional concerns involving impaired wound healing, lipid abnormalities, proteinuria and pneumonitis. A shared molecular binding protein does not mean drugs have identical indications, adverse effects or trough targets.
Routes and pharmacokinetics are drug-specific
Sirolimus tablets are oral medicines; it is incorrect to classify all mTOR inhibitors as parenteral. Tacrolimus formulations also have distinct administration requirements. Whole-blood concentration monitoring is important for tacrolimus and sirolimus, but this does not imply that every immunosuppressant has a routine trough-level target.1,4
Mycophenolate mofetil and delayed-release mycophenolic acid formulations are not automatically interchangeable. CELLCEPT labelling requires experienced supervision because their absorption characteristics differ. Changes to formulation or combination therapy need planned review.2
Therapeutic drug monitoring and CYP interactions
| Drug | Pharmacokinetic concern | Action |
|---|---|---|
| Tacrolimus | Metabolism and transport involve CYP3A and P-glycoprotein; formulation and intestinal absorption affect concentrations. | Measure formulation-appropriate whole-blood troughs plus creatinine, potassium and blood pressure. |
| Sirolimus | Longer half-life and CYP3A/P-glycoprotein interactions. | Plan concentration monitoring and laboratory review after dose or interacting-drug changes. |
| Mycophenolate | Prodrug conversion to mycophenolic acid, with enterohepatic recirculation and formulation variability. | Check adherence, blood counts and formulation changes; not routine interchangeable substitution. |
| Azathioprine | Thiopurine metabolism affected by TPMT, NUDT15 and xanthine oxidase. | Review pharmacogenetics and allopurinol/febuxostat interactions; monitor blood counts. |
| Rituximab | Monoclonal antibody with long-lasting pharmacodynamic B-cell effects. | Review infections, HBV status and immunization response rather than using a routine small-molecule trough target. |
Strong CYP3A inhibitors such as selected azole antifungals or macrolide antibiotics can raise tacrolimus concentrations, increasing nephrotoxicity, while enzyme inducers can reduce exposure and risk rejection. Avoid assuming that a stable transplant dose remains safe when a new medicine, herbal product or formulation is introduced.1
Interactions that can cause serious harm
Tacrolimus exposure rises with CYP3A inhibitors and falls with inducers. Starting or stopping interacting drugs can require prompt concentration checks and dose adjustment. Nephrotoxic co-medications increase concern even when tacrolimus is not primarily eliminated by the kidneys.1
Allopurinol inhibits a pathway involved in azathioprine inactivation. When the combination is deliberately used, substantial azathioprine dose reduction and close monitoring are required. Concomitant febuxostat is not recommended by the IMURAN label. TPMT or NUDT15 testing does not replace regular blood-count monitoring.5
2025 CPIC update: TPMT and NUDT15 for azathioprine
The Clinical Pharmacogenetics Implementation Consortium (CPIC) 2025 update, published in 2026, provides refined dosing recommendations for azathioprine, mercaptopurine and thioguanine based on TPMT and NUDT15 genotypes. Both enzymes are important in thiopurine disposition; reduced-function variants increase exposure to toxic thiopurine metabolites and the risk of severe, potentially fatal myelosuppression.8
For TPMT or NUDT15 intermediate metabolizers, the guideline recommends considering a lower starting dose when the usual starting dose is high; the compound intermediate metabolizer phenotype (intermediate function in both genes) can require more reduction than either variant alone. For poor metabolizers, particularly in nonmalignant inflammatory conditions, CPIC advises considering an alternative nonthiopurine immunosuppressant instead of full-dose azathioprine.8
Genotyping is not a guarantee against toxicity. Even normal metabolizers can develop cytopenias, infection, pancreatitis or liver problems; CBC and liver monitoring remain necessary. The interaction with allopurinol can cause severe marrow suppression unless a specialist deliberately changes the azathioprine dose, and concomitant febuxostat is generally contraindicated or not recommended under product labeling.5,8
Safety and monitoring
Tacrolimus: nephrotoxicity is an important warning, while its boxed warning specifically addresses malignancies and serious infections. Monitor drug exposure and renal function according to the transplant or disease-specific protocol.1
Sirolimus: adverse effects include impaired wound healing, hyperlipidemia, proteinuria and noninfectious pneumonitis. These risks influence selection and follow-up, especially around surgery and in patients with new respiratory symptoms.4
Mycophenolate: its boxed warning includes embryofetal toxicity, malignancies and serious infections. Pregnancy exposure is associated with miscarriage and congenital malformations. Pregnancy planning, prevention counselling and consideration of safer alternatives are essential; patients should not independently stop transplant treatment.2
Rituximab: screen for hepatitis B using HBsAg and anti-HBc before treatment. Current or previous infection requires expert planning for monitoring and possible antiviral therapy. Reactivation can occur after treatment has ended. Infusion reactions and progressive multifocal leukoencephalopathy are additional serious concerns.6
Adalimumab: assess tuberculosis risk and test for latent infection before treatment; treat latent tuberculosis when indicated. Do not initiate during an active infection. Negative baseline screening does not eliminate the need to monitor for infection during treatment.3
Rituximab: infections and prolonged B-cell effects
Rituximab targets CD20-positive B cells. Its major risks include serious infusion reactions, hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML) due to JC virus. Before treatment, evaluate HBsAg and anti-HBc; patients with evidence of current or past HBV need specialist decisions about antiviral prophylaxis or close monitoring. Reactivation can occur many months after the last infusion, so limited early follow-up is insufficient.6
New neurological deficits, altered behavior, difficulty speaking or progressive gait disturbance in someone exposed to rituximab need urgent evaluation for possible PML or another serious cause. Infusion centers must be prepared for hypersensitivity and cytokine-related reactions. Rituximab-related B-cell depletion may also reduce response to vaccination even after the drug concentration has declined.
Mycophenolate: pregnancy and reproductive counseling
Mycophenolate mofetil and other mycophenolic acid products inhibit inosine monophosphate dehydrogenase, limiting de novo guanosine synthesis and lymphocyte proliferation. The U.S. boxed warning includes embryofetal toxicity, serious infection and malignancy, and exposure during pregnancy is associated with a high risk of miscarriage and congenital malformations. Before conception, a transplant or rheumatology specialist must plan a safer regimen and the timing of changes.2
Never advise a transplant patient to stop mycophenolate abruptly when pregnancy is suspected without urgent specialist contact: interruption can precipitate rejection. The correct balance involves reproductive counseling, contraception, exposure reporting and disease-specific replacement therapy. Similar caution applies to methotrexate and other reproductive-risk immunosuppressants, although labels and waiting periods differ.
Vaccination and individualized care
Severe immunosuppression generally precludes live vaccines. Vaccination decisions should consider the exact medicine, treatment intensity and immune status rather than assuming every vaccine is contraindicated. Pregnancy, breastfeeding and organ impairment similarly require product-specific assessment. Follow-up should balance disease control against infection, malignancy and organ-toxicity risks.7,2,1
Vaccination timing during immune suppression
CDC recommends, when feasible, giving needed non-live vaccines at least two weeks before starting substantial immunosuppression and live vaccines at least four weeks before. Live vaccines are often contraindicated during severe immune suppression, whereas non-live vaccines may still be appropriate even if the response is lower. B-cell-depleting agents such as rituximab can impair vaccine responses for an extended period, with guidance on delaying certain vaccines for six months or longer after treatment depending on the vaccine and condition.9
These are general best practices, not automatic stop/restart instructions. A patient with high rejection or flare risk should not postpone urgent immunosuppressive treatment merely to satisfy a routine vaccine interval without clinician review. RSV, influenza, pneumococcal, COVID-19 and other immunizations should follow the current local age- and risk-based schedule.
For active and passive immunization principles, see vaccines and sera: pharmacology and post-exposure prophylaxis.
Practical immunosuppressant monitoring checklist
| Assessment | Why it matters |
|---|---|
| Medication reconciliation | Identify CYP3A modifiers, interacting antibiotics, herbal products and thiopurine interactions. |
| CBC, kidney and liver tests | Detect cytopenias, nephrotoxicity, hepatotoxicity and infection-related changes. |
| Blood pressure, lipids and glucose | Identify metabolic effects of calcineurin inhibitors, steroids or mTOR agents. |
| Hepatitis B and TB screening | Assess reactivation risk before selected biologics or stronger regimens. |
| Drug concentration monitoring | Relevant for tacrolimus/sirolimus and selected medicines, not every immunosuppressant. |
| Vaccines, infections and reproductive planning | Balance disease control against serious infection and fetal risks. |
Frequently asked questions
Do tacrolimus and sirolimus inhibit the same enzyme?
No. Both bind FKBP-12, but tacrolimus inhibits calcineurin, while sirolimus inhibits mTOR.
Does a normal TPMT test eliminate azathioprine risk?
No. NUDT15 variants and other sources of marrow suppression still matter, and blood-count monitoring remains necessary.8
Can rituximab reactivate old hepatitis B?
Yes. HBV reactivation can occur in patients with evidence of prior exposure, so screen and plan monitoring/prophylaxis.6
Should mycophenolate be stopped suddenly if pregnancy is suspected?
No unsupervised change; urgent transplant/obstetric review is necessary because both fetal exposure and rejection are serious risks.
Can patients on immunosuppressants receive any vaccines?
Often yes for appropriate non-live vaccines, but response may be lower and live vaccines require individualized assessment.9
References
- National Library of Medicine. PROGRAF (tacrolimus) : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b
- National Library of Medicine. CELLCEPT (mycophenolate mofetil) : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37241e87-4af4-4dc3-a1aa-ea6f20d8dc40
- National Library of Medicine. HUMIRA (adalimumab) : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d
- National Library of Medicine. Sirolimus tablets : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc81cb86-61e1-4622-b2ce-cde263143aa0
- National Library of Medicine. IMURAN (azathioprine) : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d62b6e4-a9d4-4818-e063-6394a90aa208
- National Library of Medicine. RITUXAN (rituximab) : prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563
- Centers for Disease Control and Prevention. Contraindications and precautions [Internet] [cited 2026 Nov 10]. Available from: https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
- Maillard M, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clin Pharmacol Ther. 2026;119(4):916–927. doi:10.1002/cpt.70209. Full text.
- Centers for Disease Control and Prevention. Altered immunocompetence: best practices for immunization [Internet]. Available from: CDC guidance [cited 2026 Nov 10].
⚠️ Medical Disclaimer
This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.
The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.